SCHEMBL13615168

SCHEMBL13615168

CC(C)(C)c1ccc(NS(=O)(=O)c2cccc(C(F)(F)F)c2)cc1F

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B2 P37059 1/20 0.61
NR3C1 P04150 1/20 0.56
PGR P06401 1/20 0.56
AR P10275 1/20 0.56
ESR2 Q92731 1/20 0.56
FFAR1 O14842 2/20 0.54
FFAR4 Q5NUL3 2/20 0.54
CDK1 P06493 2/20 0.54
CCNB1 P14635 2/20 0.54
CCNA2 P20248 2/20 0.54
CDK2 P24941 2/20 0.54
CDK7 P50613 2/20 0.54
CCNH P51946 2/20 0.54
CCNA1 P78396 2/20 0.54
TSHR P16473 1/20 0.54
CA1 P00915 1/20 0.51
CA2 P00918 1/20 0.51
MMP1 P03956 1/20 0.51
MMP2 P08253 1/20 0.51
MMP9 P14780 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13615099 0.88 HSD17B2 (0.68) HSD17B2NR3C1PGRARESR2
SCHEMBL13615206 0.86 FFAR4 (0.60) FFAR1FFAR4CDK1CCNB1CCNA2
SCHEMBL26075671 0.85 HSD17B2 (0.72) HSD17B2NR3C1PGRARESR2
SCHEMBL13852843 0.85 KMT2A (0.53) HSD17B2PGRFFAR1FFAR4CDK1
SCHEMBL13852803 0.84 HSD17B2 (0.58) HSD17B2NR3C1PGRARESR2
SCHEMBL13615211 0.84 PKM (0.60) HSD17B2PGRKMT2AMAPTMEN1
SCHEMBL13629410 0.82 HSD17B2 (0.61) HSD17B2NR3C1PGRARESR2
SCHEMBL13615138 0.81 PGR (0.58) PGRFFAR4HDAC1HDAC8PTPN2
SCHEMBL6844057 0.81 CDK1 (0.65) HSD17B2FFAR1FFAR4CDK1CCNB1
SCHEMBL7572806 0.80 NR3C1 (0.69) HSD17B2NR3C1PGRARESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275593-A1 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors NOVARTIS AG 2009-11-05 US disclosed
US-20090118277-A1 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors NOVARTIS AG 2009-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118277-A1 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors TIE1, TEK, MATK HSD17B2 4198/4885NR3C1 2664/4885PGR 1506/4885
US-20090275593-A1 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors TIE1, TEK, MATK HSD17B2 4325/4885NR3C1 2902/4885PGR 1648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.